Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

  • STATUS
    Recruiting
  • participants needed
    10000
  • sponsor
    Collège des Pneumologues des Hôpitaux Généraux
Send
Updated on 19 February 2024
See if I qualify
cancer
lung cancer
liquid biopsy

Summary

Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade.

Primary endpoint:

Estimate 1-year- and 5-year-mortality rates in patients with PLC.

Secondary endpoints:

  • Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
  • Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
  • Estimate prognostic factors
  • Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies
  • Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies

Details
Condition Pulmonary Disease, Lung Neoplasm, lung cancer, lung cancer
Age 18years - 100years
Clinical Study IdentifierNCT04402099
SponsorCollège des Pneumologues des Hôpitaux Généraux
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age 18 years
Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020
Follow-up by a lung specialist at a General Hospital
Oral informed consent date of collected sample

Exclusion Criteria

Age < 18 years
Secondary lung cancer
Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
Previous enrolment in the study
Freedom deprived patient following a legal or administrative decision
Patient unable to give his(her) consent
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
lung cancer
liquid biopsy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.